BRIM BiotechnologyTPE:6885 -0.46%40 Quick Ratio is 18.05 as of Dec. 2025, which is 28% below its 10-year median of 24.99. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, BRIM Biotechnology ranks better than 90.5% on this metric.
BRIM Biotechnology has a quick ratio of 18.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for BRIM Biotechnology's Quick Ratio or its related term are showing as below:
TPE:6885'
s Quick Ratio Range Over the Past 10 Years
Min: 3.47 Med: 24.99 Max: 40.74
Current: 18.05
During the past 7 years, BRIM Biotechnology's highest Quick Ratio was 40.74. The lowest was 3.47. And the median was 24.99.
TPE:6885's Quick Ratio is ranked better than 90.5% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs TPE:6885: 18.05
BRIM Biotechnology (TPE:6885) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BRIM Biotechnology Quick Ratio Related Terms
BRIM Biotechnology Quick Ratio Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6885 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, BRIM Biotechnology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRIM Biotechnology Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BRIM Biotechnology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BRIM Biotechnology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BRIM Biotechnology's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIM Biotechnology (TPE:6885) has a Quick Ratio of 18.05 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BRIM Biotechnology and its competitors. This is 28% below median its historical median of 24.99. Over the past decade, BRIM Biotechnology's Quick Ratio has ranged from 3.47 to 40.74. According to the industry distribution chart, BRIM Biotechnology ranks #134 out of 1410 companies in the Biotechnology industry, placing it in the top 9.5%.
Is BRIM Biotechnology's Quick Ratio too high?
BRIM Biotechnology's current Quick Ratio of 18.05 is 28% below median its 10-year median of 24.99. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 40.74. The Biotechnology industry median Quick Ratio is 3.60. BRIM Biotechnology's value of 18.05 is 401.4% above this industry median. Based on the distribution chart, BRIM Biotechnology ranks #134 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BRIM Biotechnology ranks #134 out of 1410 companies for Quick Ratio. This places BRIM Biotechnology in the top 10% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. BRIM Biotechnology's value of 18.05 is 401.4% above this benchmark. Historically, BRIM Biotechnology's own Quick Ratio has ranged from 3.47 to 40.74 over the past decade. While the company's 10-year median is 24.99 vs. the industry median of 3.60, BRIM Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRIM Biotechnology's current Quick Ratio of 18.05 is 401.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BRIM Biotechnology and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRIM Biotechnology's current Quick Ratio is 18.05, which is 28% below median its own 10-year median of 24.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current Quick Ratio is 18.05, which is 28% below median its 10-year median of 24.99 and 401.4% above the Biotechnology industry median of 3.60. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Quick Ratio is 18.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
Quick Ratio: 18.05 (28% below median its 10-year median of 24.99)
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
Industry Position: 401.4% above the Biotechnology median (#134 of 1410)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
